Manufacturer or GPO Program year 2025 Source: CMS Open Payments

Medicure Pharma Inc.

NJ, United States

CMS manufacturer 100000136550

Open in the dashboard

General payments

$303,346

2,413 payments

Research payments

$145,168

6 payments

Ownership & investment interest

$0

None reported

Through program year 2025, Medicure Pharma Inc. reported paying $303,346 in general payments and $145,168 in research payments to U.S. physicians, teaching hospitals and other recipients.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

10 rows
Year Kind Amount Payments
2025 General $47,943 236
2024 General $27,667 219
2024 Research $20,168 2
2023 General $15,239 167
2022 General $38,028 370
2021 General $39,147 865
2020 General $71,676 301
2020 Research $66,946 2
2019 General $63,646 255
2019 Research $58,054 2

Breakdown

Top recipients General payments · program year 2025
  1. Zaid Jabbar Internal Medicine · Oak Brook, IL $7,500 1 payment
  2. John Isaac Interventional Cardiology · Houston, TX $5,000 1 payment
  3. Xu He Internal Medicine · Redlands, CA $5,000 1 payment
  4. Nathaniel Lebowitz Cardiovascular Disease · Fort Lee, NJ $3,850 1 payment
  5. Thomas Barringer Family Medicine · Charlotte, NC $2,500 1 payment
  6. Maha Zikra Endocrinology, Diabetes & Metabolism · Orlando, FL $2,500 1 payment
  7. Alan Brown Cardiovascular Disease · Naperville, IL $2,500 1 payment
  8. Gregory Pokrywka Internal Medicine · Towson, MD $2,500 1 payment
  9. Glenn Davison Cardiovascular Disease · Chesterfield, MO $2,500 1 payment
  10. Robert Hauser Neurology · Tampa, FL $800 1 payment
Top research recipients Research payments · program year 2024
  1. Childrens Hospital Colorado Teaching hospital · CO $11,700 1 payment
  2. Childrens Hospital Corporation Teaching hospital · MA $8,468 1 payment
Products the payments named General payments · program year 2025
  1. Zypitamag Cardiology $47,943 100% · 236 recipients

Each share is of this company’s general payments naming a product in 2025. A payment can name up to five products, so these amounts overlap.

Specialties paid General payments · program year 2025
  1. Internal Medicine $16,090 34% · 48 practitioners
  2. Cardiovascular Disease Internal Medicine $9,678 20% · 20 practitioners
  3. Interventional Cardiology Internal Medicine $5,586 12% · 6 practitioners
  4. Family Medicine $3,793 8% · 40 practitioners
  5. Endocrinology, Diabetes & Metabolism Internal Medicine $3,680 8% · 15 practitioners

The top 5 of 20 specialties; each share is of this company’s general payments to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Illinois $10,000 21% · 2 recipients
  2. Florida $8,690 18% · 129 recipients
  3. Texas $5,600 12% · 3 recipients
  4. California $5,188 11% · 5 recipients
  5. North Carolina $4,475 9% · 31 recipients

The top 5 of 22 states; each share is of this company’s general payments in 2025 where a state was reported.

The top 25 states, free in the app

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $136,208 279 payments
  2. Food and Beverage $85,946 2,013 payments
  3. Consulting Fee $77,726 117 payments
  4. Travel and Lodging $3,465 4 payments
2,413 general · 6 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record